The Strategist

Moderna sets to produce drugs in China

07/06/2023 - 08:03

Major pharmaceutical companies want to increase production in China because of the country's aging population, rise of chronic diseases, and gastrointestinal ailments.

A contract has been reached by American company Moderna to produce matrix RNAi-based medicines for the Chinese market, reported The Financial Times.

Drugs created in accordance with this agreement will only be used by Chinese citizens, who deal with many of the same health issues as other populations worldwide. “We are moving ahead with our plans to use mRNA medications to benefit patients,” the business said in a statement.

Major pharmaceutical companies, according to the article, are still interested in increasing their manufacturing in China. The country faces issues including an aging population, the rise of chronic diseases, and gastrointestinal problems brought on by Western diets that are unusual for Chinese people but are nevertheless widely adopted. This market has recently become even more alluring thanks to the Chinese government's recent acceleration of the approval procedure for novel medications.

Moderna did not respond to inquiries about whether the mRNA drug agreement will cost $1 billion or about the particular medications the business plans to create in China.